ALMC-1 Plasma Cell Myeloma Cell Line

Each vial contains >1X10⁶ viable cells.

Cells are tested negative for infectious diseases by a Human Essential CLEAR panel by Charles River Animal Diagnostic Services.

Cells are verified to be of human origin and negative for inter-species contamination from mouse, rat, Chinese hamster, Golden Syrian hamster, and Non-human Primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services

Cells are negative for mycoplasma contamination.

Primary systemic amyloidosis is a plasma cell disease characterized by deposition of misfolded immunoglobulin (Ig) light chain products as amyloid fibrils throughout vital tissues and organs. Amyloidosis may present as a range of symptoms, including nervous system dysfunction, swelling, fatigue, and pain in the extremities (1). Patients with amyloidosis often suffer from other plasma cell diseases such as multiple myeloma, making the study of amyloidosis and development of potential targeted treatments extremely challenging.ALMC-1 was the first plasma cell amyloidosis cell line isolated and is characterized by c-myc amplification and deletion of the tumor suppressor p53 (2). The Ig lambda secreted by ALMC-1 cells has been shown to form amyloid fibrils in vitro (2). ALMC-1 cells proliferate in presence of IL-6, a critical factor supporting tumor growth in the bone marrow microenvironment (2). ALMC-1 cells are hypotetraploid, express CD44, and overexpress the oncogene MAFB (2). The ALMC-1 plasma cell myeloma cell line represents a valuable and clinically relevant model for amyloidosis and studies of the mechanisms of myeloma progression. SourceThe ALMC-1 cell line was isolated from bone marrow of a 50-year old female patient with amyloidosis and later diagnosed with multiple myeloma (3).References1. J Am Coll Cardiol 2016; 68(12): 1323-1341.2. Blood 112 Suppl 2008; 1: 2732a-2832a.3. Cancer Res 1993; 53:5320-5327.

The ALMC-1 plasma cell myeloma cell line is a clinically relevant model for amyloidosis and studying the mechanisms of myeloma progression.

The cells should be stored in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.